[Treatment of hyperphosphatemia with sevelamer in patients with chronic renal failure] - PubMed
[Article in Spanish]
Affiliations
- PMID: 15219089
Free article
Review
[Treatment of hyperphosphatemia with sevelamer in patients with chronic renal failure]
[Article in Spanish]
M Suñer et al. Nefrologia. 2004.
Free article
Abstract
Sevelamer is a recent phosphate binder that is mineral-free, and represents a great advance in the treatment of hyperphosphatemia in patients with hypercalcemia and/or gastric intolerance to calcium-based phosphate binders. The communications about the experience with the use of sevelamer in patients non-yet in dialysis is scanty. The aim of our study is to investigate retrospectively the gastrointestinal tolerance of sevelamer, their efficacy as phosphate binder and other parameters in a group of 89 patients with chronic renal failure in predialysis. We have analysed the effects of sevelamer at baseline and after 1, 3 and 6 months on the following data and parameters: calcium, phosphate, intact PTH, venous bicarbonate, urea, creatinine, creatinine clearance, side-effects, number of patients that were discontinued, and co-treatment during the study period with phosphate-based binders, calcitriol, lipid-lowering drugs and sodium bicarbonate.
Results: 19 patients (21.3%) refused to continue with sevelamer at the first month (16 patients had digestive intolerance and 3 several symptoms). Serum phosphate fell at 3 months (5 +/- 0.8 mg/dl basal vs 4.8 +/- 0.7 mg/dl, p = 0.02) and 6 months (5 +/- 0.8 mg/dl basal vs 4.7 +/- 0.9 mg/dl, p = 0.07). Serum calcium fell at 6 months (9.8 +/- 0.7 mg/dl basal vs 9.4 +/- 0.6 mg/dl, p = 0.03). Venous bicarbonate and iPTH were unchanged, but the quantity of sodium bicarbonate administered increased significantly. Blood cholesterol fell at 1 months (193 +/- 49 mg/dl basal vs 173 +/- 52 mg/dl, p = 0.001) and 3 months (205 +/- 49 mg/dl basal vs 170 +/- 49 mg/dl, p = 0.004), in spite of a significant reduction of the dose of statins.
Conclusions: Sevelamer is an effective phosphate binder in predialysis patients and also reduces significantly the serum cholesterol, improving the blood lipid profile. The levels of venous bicarbonate remained unchanged, at expenses of an increment in the dose of sodium bicarbonate supplementation.
Similar articles
-
Sturtevant JM, Hawley CM, Reiger K, Johnson DW, Campbell SB, Burke JR, Bofinger A, Isbel NM. Sturtevant JM, et al. Nephrology (Carlton). 2004 Dec;9(6):406-13. doi: 10.1111/j.1440-1797.2004.00338.x. Nephrology (Carlton). 2004. PMID: 15663645
-
Burke SK, Dillon MA, Hemken DE, Rezabek MS, Balwit JM. Burke SK, et al. Adv Ren Replace Ther. 2003 Apr;10(2):133-45. doi: 10.1053/jarr.2003.50016. Adv Ren Replace Ther. 2003. PMID: 12879374
-
Gallieni M, Cozzolino M, Carpani P, Zoni U, Brancaccio D. Gallieni M, et al. J Nephrol. 2001 May-Jun;14(3):176-83. J Nephrol. 2001. PMID: 11439741
-
Pai AB, Smeeding JE, Brook RA. Pai AB, et al. Curr Med Res Opin. 2004 Jul;20(7):991-9. doi: 10.1185/030079904125004015. Curr Med Res Opin. 2004. PMID: 15265243 Review.
Cited by
-
Bolasco P. Bolasco P. Clin Cases Miner Bone Metab. 2009 Sep;6(3):210-9. Clin Cases Miner Bone Metab. 2009. PMID: 22461248 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical